Clinical Trial Update: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating the safety and efficacy of PLB1004 in patients with EGFR exon 20 insertion-mutant advanced or metastatic non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PLB1004

Snippet

Sponsor: Avistone Biotechnology Co., Ltd. | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: RECRUITING